The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | Gilteritinib in R/R AML
Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the use of gilteritinib, a tyrosine kinase inhibitor, in relapsed/refractory (R/R) FLT3m+ acute myeloid leukemia (AML) patients. Dr Daver discusses the results of the ADMIRAL study (NCT02421939), evaluating gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML, as well as an ongoing study evaluating gilteritinib in combination with azacitidine. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
